Special Issue "Matrix Glycans as Multifunctional Pathogenesis Factors and Therapeutic Targets in Cancer"
Deadline for manuscript submissions: 28 February 2022.
Interests: proteoglycans; glycosaminoglycans; syndecans; heparan sulfate; cancer cell biology; microRNA; cancer stem cells
Cancer is a leading cause of mortality within the aging population. Therapeutic targeting is hampered by the complexity of the disease, which includes not only molecular changes within the tumor cell itself, but also within its microenvironment. Tumor angiogenesis, tumor–stroma interactions, interactions with immune cells and the extracellular matrix and cancer stem cell niches allow for malignant cell survival and promote metastasis, the leading cause for cancer-associated mortality. Proteoglycans (PGs) and glycosaminoglycans (GAGs) – structurally diverse carbohydrates of the extracellular matrix and cell surfaces – have emerged as novel biomarkers and molecular players both within tumor cells and their microenvironment, as they integrate signals from growth factors, chemokines and integrins, and cell–cell and cell–matrix adhesion. Furthermore, most constituents of the extracellular matrix are glycosylated, including large structural glycoproteins such as collagens, laminins, and tenascins, with important implications for molecular interactions and functions. Matrix glycoproteins are further modulated by degradative and editing enzymes such as heparanases and HSulfs. Importantly, their expression is dysregulated in numerous tumor entities, and modulates all molecular steps towards cancer metastasis. Pharmacological interference with their function thus emerges as an attractive multitargeted antitumoral approach that simultaneously acts at multiple levels of disease progression.
This Special Issue of Cancers, therefore, encompasses new research articles and timely reviews on all aspects of the role of matrix glycans in human cancer.
Prof. Dr. Ludwig Kiesel
Prof. Dr. Martin Götte
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2400 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- cancer, cancer therapy
- tumor microenvironment
- extracellular matrix